<DOC>
	<DOCNO>NCT00021034</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness taurolidine treat patient recurrent ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cancer .</brief_summary>
	<brief_title>Taurolidine Treating Patients With Recurrent Ovarian Epithelial Cancer , Fallopian Tube Cancer , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose taurolidine positive second-look surgery patient recurrent ovarian , fallopian tube , primary peritoneal cancer . II . Determine dose-limiting toxicity safety drug patient . OUTLINE : This dose-escalation study . Patients receive taurolidine intraperitoneally weekly week 1-3 7-9 absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos taurolidine maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Patients follow every 3 week 9 week . PROJECTED ACCRUAL : A maximum 15 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Taurolidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal adenocarcinoma Stage IIC high diagnosis Successfully receive prior chemotherapy Undergone initial cytoreductive surgery Evidence gross disease secondlook surgery PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL AST and/or ALT le 3 time upper limit normal No clinically significant PT/PTT abnormality Renal : Creatinine le 1.7 mg/dL Other : No known hypersensitivity taurolidine excipients No clinically significant disease would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : At least 30 day since prior investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>